Germline testing for inherited genetic variants is recommended to many people with cancer, yet such useful testing is notably underutilized.

Choosing NGS first rather than Single-Gene Testing in cancer is a financially effective and diagnostically efficient strategy in many cases.

We compared awareness in oncologists of selected biomarkers to the prevalence of actionable oncogenic mutations across cancers.

NGS is useful for diagnosis and prognosis but also for treatment decisions and resistance monitoring yet it is not consistently used.